SBRT-SG-01: final results of a prospective multicenter study on stereotactic body radiotherapy for liver metastases

期刊论文
发表日期：

2024年3月2日

查看全文

María-Carmen Rubio Rodríguez,
Xin Chen-Zhao,
Ovidio Hernando,
Sonia Flamarique,
Pedro Fernández-Letón,
Maider Campo,
Mercedes López,
Maitane Rodríguez,
Daniel Zucca,
Daniel Martínez,
Emilio Sánchez-Saugar,
Fernando Mañeru,
Juan García Ruiz-Zorrilla,
Paz García de Acilu,
Jeannette Valero,
Angel Montero,
Raquel Ciérvide,
Beatriz Alvarez,
Mariola García-Aranda,
Rosa Alonso,
Miguel Angel de la Casa,
Leyre Alonso,
Mónica Nuñez,
Jaime Martí,
Fernando Arias

摘要

Objective

This study aimed to assess the efficacy and tolerability of stereotactic body radiation therapy (SBRT) for the treatment of liver metastases.

Methods

Patients with up to 5 liver metastases were enrolled in this prospective multicenter study and underwent SBRT. Efficacy outcomes included in-field local control (LC), progression-free survival (PFS), and overall survival (OS). Acute and late toxicities were evaluated using CTCAE v.4.0.

Results

A total of 52 patients with 105 liver metastases were treated between 2015 and 2018. The most common primary tumor was colorectal cancer (72% of cases). Liver metastases were synchronous with the primary tumor diagnosis in 24 patients (46.2%), and 21 patients (40.4%) presented with other extrahepatic oligometastases. All patients underwent intensity-modulated radiation therapy (IMRT)/volumetric-modulated arc therapy (VMAT) with image-guided radiation therapy (IGRT) and respiratory gating, and a minimum biologically effective dose (BED10Gy) of 100 Gy was delivered to all lesions. With a median follow-up of 23.1 months (range: 13.4–30.9 months) since liver SBRT, the median actuarial local progression-free survival (local-PFS) was not reached. The actuarial in-field LC rates were 84.9% and 78.4% at 24 and 48 months, respectively. The median actuarial liver-PFS and distant-PFS were 11 and 10.8 months, respectively. The actuarial median overall survival (OS) was 27.7 months from SBRT and 52.5 months from metastases diagnosis. Patients with lesion diameter ≤ 5 cm had significantly better median liver-PFS (p = 0.006) and OS (p = 0.018). No acute or late toxicities of grade ≥ 3 were observed.

Conclusions

This prospective multicenter study confirms that liver SBRT is an effective alternative for the treatment of liver metastases, demonstrating high rates of local control and survival while maintaining a low toxicity profile.